Regeneron stock increased by 19% over the past month, driven by strong third-quarter earnings. But is Gilead the better pick?

Several pharmaceutical companies awaiting a decision from U.S. authorities on their drug applications are set to get them ...

REGN stock is presently trading nearly 38% lower than its 1-year peak, and is also being traded at a P/S multiple that is beneath the average for the past 3 years.

Wondering if Regeneron Pharmaceuticals is a hidden gem or just fairly priced? You are not alone; investors everywhere are ...

Return on Assets (ROA): Regeneron Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.67%, the company showcases ...

Multiple analysts have issued price targets for $REGN recently. We have seen 17 analysts offer price targets for $REGN in the last 6 months, with a median target of ...

Regeneron Pharmaceuticals (REGN) shares have been in focus recently, attracting investor interest thanks to their steady revenue and net income growth over the past year. The stock has gained 16% in ...

Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 5.33% in ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Regeneron Pharmaceuticals (REGN) is forecasting annual earnings growth of 7.41%, with revenue also projected to rise by 7% per year, both lagging the broader US market's expected pace. The company’s ...